Information  X 
Enter a valid email address

Destiny Pharma PLC (DEST)

  Print      Mail a friend

Thursday 07 January, 2021

Destiny Pharma PLC

Destiny Pharma: Directors Dealings

RNS Number : 8344K
Destiny Pharma PLC
07 January 2021

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Directors Dealings

Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces the following Directors' dealings :

Nick Rodgers, Chairman, purchased 9,000 Ordinary Shares at a price of 88.0p per Ordinary Share. Following the transaction, his total beneficial interest is 47,462 Ordinary Shares, representing 0.08% of the total issued share capital of the Company.


Details of the full notification received by the Company are set out below:



Details of the person discharging managerial responsibilities / person closely associated



Nick Rodgers


Reason for the Notification





Initial notification/Amendment

Initial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Destiny Pharma plc





Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each in Destiny Pharma Plc

Identification code



Nature of the transaction

Purchase of Ordinary Shares


Price(s) and volume(s)

88.0 pence per Ordinary Share

9,000  Ordinary Shares


Aggregated information:

Aggregated volume



See 4c) above 



Date of the transaction

6 January 2021


Place of the transaction

London Stock Exchange, AIM Market



Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)

finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)

WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

Optimum Strategic Communications

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus



The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Ab out Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.


For further information, please visit


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t